24th Aug 2023 18:36
(Alliance News) - Pfizer Inc on Thursday said the European Commission has granted marketing authorisation for Abrysvo.
The New York City-based pharmaceutical firm said that Abrysvo is the first and only RSV vaccine approved in the European Union for both older adults and for immunization of pregnant individuals to help protect their infants immediately from birth through six months of age.
On Thursday, Pfizer said the European Commission has granted marketing authorization for Abrysvo, the company's bivalent respiratory syncytial virus prefusion F vaccine, to help protect both infants through maternal immunization and older adults.
It explained that Abrysvo is indicated for passive protection against lower respiratory tract disease caused by RSV in infants from birth through six months of age following maternal immunization during pregnancy, as well as active immunization of individuals 60 years of age and older for the prevention of LRTD caused by RSV.
RSV is a contagious virus and a common cause of respiratory illness. The virus can affect the lungs and breathing passages of an infected individual.
"The approval of Abrysvo in Europe marks significant progress in the scientific community's efforts to provide meaningful protection against RSV, a common respiratory virus that could potentially be severe and even life-threatening, especially for infants and older adults," said Annaliesa Anderson, senior vice president and head vaccine research & development at Pfizer.
"Last year's significant number of newborns, children, and adults being hospitalized across Europe demonstrated the immense need for protection against severe RSV cases. The approval of the vaccine for both older adults and infants through maternal immunization is a triumph for public health and we hope to see a tremendous impact for future seasons."
By Sophie Rose, Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
